By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


SAGE Therapeutics 

29 Newbury Street

Boston  Massachusetts  02116  U.S.A.
Phone: n/a Fax: n/a



Start Up

Company News
Ligand Pharmaceuticals Inc. (LGND) Earns Milestone From SAGE Therapeutics For SAGE-547 4/22/2015 11:24:20 AM
SAGE Therapeutics Announces Closing Of $138 Million Public Offering Of Common Stock Including Full Exercise Of Option To Purchase Additional Shares 4/21/2015 8:40:59 AM
SAGE Therapeutics Announces First Patient Treated Under Phase 3 Expanded Access Protocol To Evaluate SAGE-547 In Patients With Super-Refractory Status Epilepticus 4/20/2015 8:01:58 AM
SAGE Therapeutics Announces Pricing Of Public Offering Of Common Stock 4/15/2015 4:05:20 PM
SAGE Therapeutics Announces Proposed Public Offering Of Common Stock 4/14/2015 7:48:26 AM
SAGE Therapeutics Announces Presentations At Upcoming Scientific Conferences 4/9/2015 6:15:03 AM
SAGE Therapeutics Announces Positive End-Of-Phase 2 Meeting With FDA And Planned Initiation Of SAGE-547 Global Phase 3 Trial In Mid-2015 4/2/2015 7:06:44 AM
SAGE Therapeutics Reports Fourth Quarter And Full Year 2014 Financial Results 2/27/2015 7:36:55 AM
SAGE Therapeutics Appoints New Vice Presidents To Lead Key Organizational Functions 2/13/2015 7:42:33 AM
SAGE Therapeutics Announces Participation In February Conference 1/28/2015 7:58:55 AM